October 2010 Latest GU Updates from ESMO
Published: Fri Apr 29, 2011 Updated:Wed Sep 14, 2011We would like to thank Dr Lori Wood for the latest GU update.
Abiraterone acetate (AA) plus low dose prednisone improves overall survival in patients with metastatic castration resistant prostate cancer (CRPCa) who have progress after docetaxel-based chemotherapy: Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study.
